Rawbank Conducts a USD 10 Million Commercial Paper to Support the Mining Industry and Strengthen the Congolese Economy
14.1.2025 11:52:00 CET | Business Wire | Press release
Rawbank, the leading bank in the Democratic Republic of Congo, announces the launch of its second issue of commercial paper for a local mining operator in the Katanga region for the sum of USD 10 million. This transaction, arranged by Rawbank's trading room, confirms the bank's role as a key player in financial innovation in the DRC, while satisfying the strategic financing needs of companies operating in major sectors of the national economy.
Following the success of its first issuance in 2022, which marked a significant step forward for the financial market in the Democratic Republic of Congo, Rawbank has affirmed its pioneering role by introducing solutions that are ever-increasingly adapted to local conditions. A major innovation in this issuance is the inclusion of a corporate guarantee - a first in the DRC - which strengthens investor security and extends the financing options available on the money market. This transaction was approved by the Central Bank of the Congo (CBC) under Instruction 50, which regulates commercial paper.
Mustafa Rawji, Chief Executive Officer of Rawbank, declared: “This transaction strengthens our leadership position in the banking sector in the DRC and underscores our commitment to support the country's economic development. By facilitating access to financing for key businesses, we are contributing to the growth and diversification of the national economy.”
Etienne Mabunda, Commercial Director of Rawbank, stated: "This second issue of commercial paper bears witness to our ability to innovate and meet the specific needs of our institutional clients. Thanks to our trading room, which complies with international standards, we were able to structure this transaction in the best possible way, thus offering our investors better yields in a competitive market environment."
The mining industry, which accounts for more than 70% of the DRC's exports, remains a vital pillar of the Congolese economy. By giving a national operator access to competitive financing, this new issuance contributes directly to boosting economic activity in the region and strengthening investor confidence while, at the same time, stimulating local savings through attractive financial products.
About Rawbank
For 23 years, with total assets of USD 5 billion, Rawbank has supported the development of the Congolese economy. The leading bank in the DRC for 12 years, Rawbank provides the most modern products and services to over 500,000 corporate, SME, and individual clients through a network of more than 100 branches across 19 provinces, a digital offering with Illicocash, internet banking, and over 250 ATMs.
Its efforts have been recognized with the African Banker Awards for Best Regional Bank in Central Africa in 2022 and 2024, a Moody’s CAA 1 rating, and ISO/IEC 20000 and ISO/IEC 27001 certifications. Rawbank’s trusted partners include IFC, BAD, TDB, BADEA, Shelter Africa, AGF, among others.
Partners who have placed their trust in RAWBANK include: AfDB, AGF, IFC, BADEA, Shelter Africa, TDB and Afrexim. For more information, visit our website:www.rawbank.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109301667/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom